Colchicine to lower heart artery swelling in HIV
Treatments studied
Part of Heart & circulation, Immune system & allergy, Infections clinical trials.
This trial tests if colchicine, a medicine for inflammation, can reduce swelling in the heart arteries of people with HIV. It may help lower the risk of heart problems in those already on a statin or similar medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 50 years old and have HIV
- Your HIV should be well-controlled with antiretroviral therapy for at least 6 months, with a low viral load for the past year
- You need a higher-than-average heart disease risk (SCORE-2 over 5%)
- You must be on a stable dose of a statin or similar cholesterol medication for the past year
- You cannot have had a heart attack, stroke, or certain other medical conditions like severe heart failure, kidney problems, or active cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking colchicine can prevent coronary artery disease (heart artery blockages) in people who have several heart risk factors but do not already have diagnosed disease. It aims to see if colchicine lowers the chance of developing heart artery problems over time.
This trial tests if a low dose of colchicine, a medicine that reduces inflammation, can help improve blood vessel and bone health in people with moderate chronic kidney disease.
This trial tests if colchicine, an anti-inflammatory medicine, can help people with a type of heart failure where the heart pumps well but is stiff and inflamed. You may join if your heart failure recently worsened and you have signs of inflammation in your blood.
This trial tests if the anti-inflammatory drug colchicine can help people hospitalized with acute heart failure and a weak heart pump. It may benefit those with elevated inflammation markers.
This trial tests whether a low-dose colchicine (LoDoCo) can help people with heart failure and inflammation feel better and exercise more. It is for adults 50 and older with HFpEF who have signs of inflammation in their blood.
This trial tests whether adding a targeted anti-inflammatory drug to standard care can prevent future heart attacks or strokes in people with high-risk chronic coronary artery disease. It is for people who have a moderate narrowing in a heart artery with a vulnerable plaque and signs of inflammation.
Hear when a new Cardiovascular Diseases (CVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.